Evidence map›Paper›PMID 38164271›Full record

ArticleJournal of Cancer2024

IGFBP5, as a Prognostic Indicator Promotes Tumor Progression and Correlates with Immune Microenvironment in Glioma.

Jiediao Lin, Guowei Huang, Qianru Zeng, Rendong Zhang, Yun Lin, Yaochen Li, Baohua Huang, Hongchao Pan

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jiediao LinCentral laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Guowei HuangDepartment of Pathology, Shantou University Medical College, Shantou, Guangdong, 515041, China.
Qianru ZengCentral laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Rendong ZhangCentral laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Yun LinCentral laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Yaochen LiCentral laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Baohua HuangDepartment of Pathology, Shantou Central Hospital, Shantou, Guangdong 515041, China.
Hongchao PanCentral laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Cancer Hospital of Shantou University Medical College · CNShantou University · CNShantou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GliomaIGFBP5Immune infiltrationInvasionPrognostic marker

Identifiers

PMID38164271
PMCPMC10751672
OpenAlexW4389340116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.